GlassScriptPhysician profile
Rosalyn Diaz
NPI 1366632093
$5,186.48
in general payments reported to CMS, 2019-2025
10 companies · $25.01 in 2025
The $25.01 reported for 2025 was less than what a typical Pediatric Gastroenterology provider received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $149 · 2021: $325 · 2022: $2,668 · 2023: $1,827 · 2024: $193 · 2025: $25.01.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,062 · Food and Beverage: $983.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,062.00 |
| Food and Beverage | $982.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $4,087.66 | 2022-2025 | |
| Abbvie INC. | $312.69 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $127.14 | 2023 | Zeposia |
| Janssen Scientific Affairs, LLC | $125.00 | 2021 | |
| Albireo Pharma, INC. | $122.03 | 2023 | Bylvay |
| Janssen Pharmaceuticals, INC | $121.95 | 2019-2023 | Stelara |
| Mirum Pharmaceuticals, INC. | $119.12 | 2024 | Livmarli |
| Takeda Pharmaceuticals U.S.A., INC. | $105.88 | 2022 | |
| Genentech, INC. | $52.31 | 2024 | Xolair |
| Pfizer INC. | $12.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rosalyn Diaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.